XXXX for acute exacerbations of @entity1030 . A controlled trial.

@entity1 @entity1667 @entity2544 @entity3416 @entity390 @entity1353 @entity114 @entity26 @entity391 @entity400 @entity207 @entity1576 @entity56 @entity1030 @entity869 @entity803 @entity4095 @entity206 @entity28787
STUDY OBJECTIVE: To determine the efficacy of intravenous @entity3416 in the treatment of @entity1 hospitalized for exacerbation of @entity1030 . DESIGN: Randomized, double-blind, placebo-controlled trial during the first 72 hours of hospitalization. @entity1 : Thirty @entity1 admitted from the emergency room or walk-in clinic with the primary diagnosis of an exacerbation of @entity1030 . Twenty-eight @entity1 completed the study; 2 @entity1 , 1 receiving placebo and 1 receiving @entity3416 , were removed from the study because of @entity1576 requiring mechanical ventilation. INTERVENTIONS: @entity1 received either intravenous @entity3416 or placebo, in addition to nebulized, inhaled 0.3 mL of a 5% solution every 6 hours; @entity1667 , 0.5 mg/kg body weight every 6 hours intravenously; @entity869 , 500 mg orally every 6 hours ( @entity803 or @entity206 - @entity207 were substituted in @entity114 - @entity56 @entity1 ); and supplemental @entity26 as needed. @entity3416 infusion rates were adjusted by an unblinded investigator to achieve @entity2544 levels of 72 to 83 mumol/L. Changes were also made in placebo infusion rates to maintain the double-blind design. MEASUREMENTS AND MAIN RESULTS: The forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) before and after @entity28787 inhalation were measured twice daily by a blinded investigator, who also administered a verbal @entity1353 index with a scale of 1 to 10 and questioned @entity1 regarding possible side effects of treatment ( @entity400 , palpitations, @entity390 , or @entity391 ). Arterial blood gas measurements at 72 hours were compared with those obtained on admission. Significant improvements in FEV1 and FVC measured before and after @entity28787 treatment and in @entity1353 occurred over time in both treatment groups (p less than 0.05 for all measurements). However, there were no significant differences between the placebo and @entity3416 groups in any of the spirometric measurements or the @entity1353 indices (p greater than 0.5 in all five analyses). The mean increases (+/- SE) in @entity4095 of 1.9 (+/- 0.5) kPa with placebo and 1.7 (+/- 0.7) kPa with @entity3416 and the mean decreases in PCO2 of 0.5 (+/- 0.4) kPa with placebo and 1.2 (+/- 0.4) kPa with @entity3416 were not significantly different (p greater than 0.6 for @entity4095 , p greater than 0.2 for PCO2).(ABSTRACT TRUNCATED AT 400 WORDS)
